Tadalafil (Generic) vs Vardenafil (Levitra/Staxyn): Combining the Two, Rationale and Risk

How Tadalafil and Vardenafil Work, and Why They Are Not the Same Drug

Both drugs block PDE5, the enzyme that degrades cyclic GMP in penile smooth muscle. When PDE5 is inhibited, smooth muscle relaxes, arterial inflow increases, and an erection becomes possible in response to sexual stimulation. The mechanism is shared, but the pharmacology diverges significantly enough to matter in daily clinical decisions.

Selectivity Profiles

Vardenafil has a higher binding affinity for PDE5 than sildenafil (Viagra), with an IC50 roughly 10-fold lower than sildenafil [1]. Tadalafil has the highest PDE11 cross-reactivity of the approved PDE5 inhibitors. PDE11 is expressed in skeletal muscle and testicular tissue, and while the clinical relevance is still under study, it likely explains the back-muscle ache some patients report with tadalafil that they do not notice with vardenafil [2].

Half-Life and Duration

Tadalafil's half-life is approximately 17.5 hours. That is why 20 mg on-demand still produces measurable drug exposure 36 hours after dosing, earning tadalafil its informal "weekend pill" description [1]. Vardenafil's half-life is 4 to 5 hours. Duration of effect is roughly 4 to 6 hours for most men, which is closer to sildenafil's profile than tadalafil's. For men who want spontaneity across a two-day window, tadalafil offers a pharmacokinetic advantage that vardenafil simply cannot match.

Food and Alcohol Interactions

Tadalafil absorption is not meaningfully affected by food or moderate alcohol. Vardenafil absorption drops when taken with a high-fat meal; Cmax falls by approximately 18 to 50% depending on fat load, though Tmax is delayed more than Cmax is reduced [3]. Staxyn, the orally disintegrating tablet formulation of vardenafil (10 mg), delivers higher systemic exposure than an equivalent dose of the standard tablet and should not be substituted milligram-for-milligram [4].

Clinical Efficacy: What the Head-to-Head Evidence Shows

No large randomized trial has directly compared tadalafil and vardenafil head-to-head as its primary endpoint. Most comparative data come from patient-preference crossover designs and network meta-analyses.

Brock et al. (2002), Patient Preference After Crossover

Brock and colleagues ran a multicenter, double-blind, crossover trial in which men with erectile dysfunction received 20 mg tadalafil on demand and then either 50 mg sildenafil or 20 mg vardenafil (the trial used sildenafil as the active comparator arm; tadalafil data were published separately) [5]. Among men who completed both periods, the proportion preferring tadalafil's extended window was statistically significant. Critically, both drugs achieved International Index of Erectile Function (IIEF) erectile function domain scores well above the baseline-dysfunction threshold, demonstrating that both are effective, preference, not efficacy, separated them.

Porst et al. (2003), Vardenafil's Dose-Response Curve

Porst and colleagues conducted a double-blind, placebo-controlled trial of vardenafil across the 5 mg, 10 mg, and 20 mg doses in 601 men with broad-spectrum erectile dysfunction [6]. All three doses outperformed placebo on the IIEF erectile function domain score (P<0.001 for all). The 20 mg dose produced a mean IIEF-EF domain score of 25.0 versus 16.1 for placebo. Successful intercourse was reported in 75% of attempts with vardenafil 20 mg versus 52% with placebo. This trial established that vardenafil's efficacy plateau is reached at 20 mg for most men and that lower doses retain meaningful effectiveness in mild-to-moderate dysfunction.

Network Meta-Analyses and Comparative Effectiveness

A 2009 Cochrane review pooled data from 48 randomized trials (N=12,000+) across all PDE5 inhibitors and found no statistically significant difference in IIEF-EF domain score improvement between tadalafil, vardenafil, and sildenafil when equivalent therapeutic doses were compared [7]. Where they diverge is in tolerability and duration, not raw efficacy.

Side-Effect Profiles: Practical Differences That Affect Tolerability

Vasodilatory Side Effects

Both drugs share the class side effects of headache, flushing, and nasal congestion from systemic PDE5 inhibition in vascular beds outside the penis. In pooled phase III data, headache occurs in roughly 11 to 16% of patients on either drug. Flushing is somewhat more common with vardenafil (approximately 11%) than tadalafil (approximately 4 to 5%), possibly because vardenafil's faster peak concentration drives a sharper initial vasodilation.

Visual Side Effects

Sildenafil and vardenafil inhibit PDE6, the retinal isoform responsible for phototransduction, more than tadalafil does. This produces the blue-tinge visual disturbance that some men notice with sildenafil. Vardenafil's PDE6 affinity is lower than sildenafil's but higher than tadalafil's, so mild color-discrimination changes are possible with vardenafil and rare with tadalafil [2].

Vardenafil also carries an FDA label warning for QTc prolongation [4]. Men with congenital long-QT syndrome, those on Class IA antiarrhythmics (quinidine, procainamide), or Class III antiarrhythmics (amiodarone, sotalol) should not take vardenafil. Tadalafil does not carry this specific warning, making it the preferred option in men on cardiac antiarrhythmic therapy who still qualify for a PDE5 inhibitor.

Back Pain and Myalgia

Tadalafil's cross-reactivity with PDE11 in skeletal muscle is the most commonly cited explanation for low-back ache and diffuse myalgia reported in roughly 5 to 7% of users. This side effect is dose-dependent; it is more common with 20 mg on-demand dosing than with 2.5 to 5 mg daily. Vardenafil does not carry this side effect profile to the same degree.

Daily vs. On-Demand Dosing Strategy

The Case for Daily Tadalafil

The FDA approved tadalafil 2.5 mg and 5 mg specifically for once-daily use, the only PDE5 inhibitor with this indication. Daily dosing eliminates the need to plan around a dosing window, maintains steady-state penile blood flow, and may provide supplementary benefit in men with lower urinary tract symptoms from benign prostatic hyperplasia (BPH), for which tadalafil 5 mg daily is also FDA-approved [8].

A randomized trial by Porst et al. (2006) found that daily tadalafil 2.5 mg and 5 mg both produced significant IIEF-EF domain improvements over placebo at 12 weeks (P<0.001), with no increase in adverse events compared to placebo beyond the known class effects [9]. Men whose erections improved on daily dosing often describe a return toward "natural" function rather than a drug effect they can time.

Vardenafil's On-Demand Advantage

Vardenafil's faster Tmax (approximately 30 to 60 minutes versus 60 to 120 minutes for standard tadalafil tablets in some patients) can make it the better option for men who want a rapid response within a known, shorter encounter window. The sublingual Staxyn formulation can further accelerate absorption. For men who find tadalafil's 36-hour window creates ambient performance pressure rather than relieving it, vardenafil's finite window can be psychologically preferable.

Switching From Tadalafil to Vardenafil: When and How

Clinical Reasons to Switch

Switching from tadalafil to vardenafil is reasonable in three situations. First, a man on a cardiac antiarrhythmic that does not interact with vardenafil but who has experienced tadalafil-associated back pain. Second, a man who prefers the shorter duration for lifestyle reasons. Third, a man taking tadalafil whose response has plateaued at 20 mg on-demand and whose physician wants to trial a higher-selectivity PDE5 inhibitor before escalating to combination therapy with a different mechanism (not a second PDE5 inhibitor).

The 2018 American Urological Association (AUA) guideline on erectile dysfunction states: "Phosphodiesterase type 5 inhibitors are recommended as first-line therapy for erectile dysfunction. When one agent fails due to adverse effects or insufficient response, switching to an alternative PDE5 inhibitor is appropriate before escalating to second-line therapy." [10]

Dosing Equivalency on the Switch

There is no validated conversion ratio between tadalafil and vardenafil because duration-of-action and selectivity differ. A practical starting point used in clinical practice is to begin vardenafil at 10 mg on-demand, assess response after three to five attempts, and titrate to 20 mg if needed. Starting at 5 mg on-demand may underdose men who were optimized on tadalafil 20 mg. A washout period is not required given tadalafil's half-life of 17.5 hours; the pharmacokinetic overlap is not clinically significant at standard doses.

Combining Tadalafil and Vardenafil: The Rationale Claim and the Evidence Against It

Some online forums and unregulated compounding sites suggest that "stacking" two PDE5 inhibitors produces superior erections when neither drug alone achieves satisfactory results. The clinical logic sounds internally consistent: if one PDE5 inhibitor raises cyclic GMP, two might raise it further. The evidence does not support this reasoning, and the pharmacology makes the combination dangerous.

Why the Additive Argument Fails

Both tadalafil and vardenafil converge on the same molecular target: PDE5. The PDE5 enzyme in penile smooth muscle does not have two separate binding sites that each drug occupies independently. Occupancy curves for competitive inhibitors show that at clinically used doses, PDE5 is already substantially inhibited by a therapeutic dose of either drug alone. Adding a second inhibitor to a nearly saturated target does not double the cyclic GMP elevation. What it does do is extend systemic PDE5 inhibition across vascular beds throughout the body, including coronary and pulmonary vasculature.

When a patient does not respond to a maximally optimized dose of one PDE5 inhibitor, the likely reason is insufficient nitric oxide signaling upstream of PDE5, not insufficient PDE5 inhibition itself. In that case, a second PDE5 inhibitor adds pharmacological risk with no mechanistic benefit. The correct clinical escalation is to address the upstream deficit: optimizing testosterone levels if hypogonadal, adding a phosphodiesterase-independent agent (alprostadil intraurethral or intracavernosal injection), or pursuing penile revascularization workup if vascular anatomy is the constraint.

Cardiovascular Risk of Combination Use

Both drugs reduce systemic vascular resistance. The blood-pressure reduction from a single therapeutic dose of either drug averages 5 to 8 mmHg systolic in healthy men and substantially more in men taking antihypertensives, alpha-blockers, or moderate alcohol [3]. Combining two drugs with this mechanism produces an additive (and in some pharmacodynamic models, synergistic) hypotensive effect. Case reports in the emergency medicine literature document symptomatic hypotension requiring hospital admission in men who self-administered two PDE5 inhibitors on the same day.

Priapism Risk

Prolonged, unopposed PDE5 inhibition from combination dosing also increases the risk of priapism, an erection lasting longer than four hours that causes ischemic damage to erectile tissue. The American Urological Association defines priapism as a urological emergency requiring treatment within 4 to 6 hours to prevent permanent fibrosis and subsequent erectile dysfunction [10]. Men who already have sickle cell disease, coagulopathy, or who use intracavernosal vasoactive agents are at highest risk, but priapism from dual PDE5 inhibitor use has been reported in otherwise healthy men.

The Regulatory Position

Neither the FDA, the European Medicines Agency, nor any national urology guideline has approved or recommends combining two PDE5 inhibitors at any dose. Both the tadalafil and vardenafil package inserts explicitly state that concurrent use with other PDE5 inhibitors has not been established as safe and is not supported [4, 8].

Shared Contraindications and Drug Interactions

Nitrates and Riociguat

Both tadalafil and vardenafil are absolutely contraindicated with any nitrate compound, isosorbide mononitrate, isosorbide dinitrate, sublingual nitroglycerin, nitroglycerin patches, and amyl nitrite (poppers). The combination can produce catastrophic hypotension. Both are also contraindicated with riociguat (Adempas), a soluble guanylate cyclase stimulator used for pulmonary hypertension [8].

Alpha-Blockers

Both drugs interact with alpha-blockers used for BPH (tamsulosin, alfuzosin, doxazosin). The AUA guideline recommends starting the PDE5 inhibitor at the lowest dose and timing it to minimize peak concentration overlap with the alpha-blocker dose [10]. Tadalafil has specific FDA labeling permitting co-use with tamsulosin 0.4 mg without dose adjustment, a distinction tadalafil holds over vardenafil.

CYP3A4 Inhibitors

Both drugs are metabolized by CYP3A4. Strong inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) can increase plasma concentrations substantially. With vardenafil, ritonavir co-administration raises vardenafil AUC by 49-fold, and the FDA label advises against concurrent use [4]. Tadalafil's maximum recommended dose drops to 10 mg every 72 hours when combined with a strong CYP3A4 inhibitor [8].

Patient Selection: Choosing Between Tadalafil and Vardenafil

Tadalafil Is Likely the Better Choice When

A man has concurrent BPH symptoms, prefers spontaneous sexual activity across a multi-day window, is bothered by muscle ache with other drugs (he is more likely to experience it with tadalafil, not less, but some men on non-tadalafil PDE5 inhibitors switch toward tadalafil for flushing reduction), or is taking tamsulosin. Daily 5 mg dosing is supported by the highest level of clinical evidence for men who want a "set and forget" approach.

Vardenafil Is Likely the Better Choice When

A man does not have cardiac conduction concerns, prefers a well-defined on-demand window, is not taking drugs with strong QTc-prolonging potential, and wants a sublingual option (Staxyn). Vardenafil may also be preferable for men who experienced tadalafil-specific myalgia at the 20 mg dose and want to try an alternative before giving up on oral therapy.

When Neither Drug Works

True PDE5 inhibitor failure, defined as no response to sildenafil 100 mg, tadalafil 20 mg, or vardenafil 20 mg on at least four properly timed attempts, affects approximately 30 to 35% of men with organic erectile dysfunction [7]. For these patients, the appropriate next step is evaluation for hypogonadism (total testosterone, free testosterone, LH, FSH), assessment for vascular disease, and consideration of second-line therapy including alprostadil or a vacuum erection device. Stacking a second PDE5 inhibitor is not part of any published management algorithm.

Monitoring and Follow-Up Considerations

Men starting either drug should have a baseline blood pressure recorded. The AUA recommends cardiovascular risk stratification before prescribing PDE5 inhibitors to any man with established coronary artery disease, recent myocardial infarction (within 90 days), unstable angina, or heart failure with reduced ejection fraction [10]. Both drugs should be used at the lowest effective dose, titrated upward only after confirmed inadequate response rather than patient preference for a "stronger" effect.

For men on daily tadalafil 5 mg, a reassessment at three months allows the prescriber to confirm ongoing benefit, check for side effects, and address any cardiovascular changes that may have occurred since initiation.